Other treatment options present their own challenges and side effects; for instance, intravitreal injections of anti-vascular endothelial growth factor (VEGF) do not completely halt DR progression, and repeated treatments increase the risk of endophthalmitis (Wykoff 2017). The gene discussed is VEGFA; the disease is endophthalmitis.